Clinical Scorecard: The New Era of Postoperative Inflammation Management
At a Glance
| Category | Detail |
|---|---|
| Condition | Post-cataract inflammation |
| Key Mechanisms | Corticosteroids inhibit pro-inflammatory prostaglandin release; NSAIDs block prostaglandin synthesis by inhibiting COX activity. |
| Target Population | Patients undergoing cataract surgery, including those with glaucoma. |
| Care Setting | Hospital outpatient department (HOPD) and ambulatory surgery center (ASC). |
Key Highlights
- Corticosteroids and NSAIDs are essential for managing postoperative inflammation.
- Intracameral and sustained-release medications reduce the burden of polypharmacy.
- Patients prefer simplified postoperative regimens with fewer drops.
- Glaucoma patients can safely use intracanalicular dexamethasone without increased IOP risk.
- Emerging sustained-release options for glaucoma treatment are being developed.
Guideline-Based Recommendations
Diagnosis
- Assess for inflammation and infection risk post-cataract surgery.
Management
- Utilize intracameral injections and sustained-release medications to minimize drop use.
Monitoring & Follow-up
- Monitor for signs of inflammation and IOP changes, especially in glaucoma patients.
Risks
- Consider the risk of cystoid macular edema in patients with glaucoma.
Patient & Prescribing Data
Post-cataract surgery patients, including those with glaucoma.
Sustained-release medications can improve adherence and reduce complexity.
Clinical Best Practices
- Use visual aids to help patients track medication schedules.
- Consider compounded drops to reduce the number of bottles.
- Opt for dropless strategies when possible to enhance patient compliance.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
